

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT MAY 06 2004 (use as many sheets as necessary)		Complete if Known	
Application Number		09/147,443	
Filing Date		01/21/1999	
First Named Inventor		Andreas Morell	
Group Art Unit		1644	
Examiner Name		Francois P. Vandervegt	
Attorney Docket Number		029860-0114	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
R	A1	BARBAS III et al., "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs," <u>Methods: A Comparison to Methods in Enzymology</u> , April 1991, pp. 119-124, Vol. 2, No. 2, Academic Press, Inc.	
	A2	CHÉRIF-ZAHAR et al., "Molecular cloning and protein structure of a human blood group Rh polypeptide," <u>Proc. Natl. Acad. Sci. USA</u> , August 1990, pp. 6243-6247, Vol. 87	
	A3	CRAWFORD et al., "Production of Human Monoclonal Antibody to Rhesus D Antigen," <u>The Lancet</u> , February 19, 1983, pp. 386-388, Vol. I, No. 8321	
	A4	DZIEGIEL et al., "Recombinant Antibody Against the Erythrocyte Antigen, Rhesus D," Abstract No. T513, <u>Journal of Cellular Biochemistry</u> , February 26-April 17, 1994, p. 212, Supplement 18D, Wiley-Liss	
	A5	HUGHES-JONES, "Human Monoclonal Antibodies and Haemolytic Disease of the Newborn," <u>British Journal of Haematology</u> , November 1988, pp. 263-265, Vol. 70, No. 3, Blackwell Scientific Publications	
	A6	ISSITT, "Genetics of the Rh blood group system: some current concepts," <u>Medical Laboratory Sciences</u> , 1988, pp. 395-404, Vol. 45, Blackwell Scientific Publications	
	A7	KOZBOR et al., "The production of monoclonal antibodies from human lymphocytes," <u>Immunology Today</u> , 1983, pp. 72-79, 1983, Vol. 4, No. 3, Elsevier Science Publishers B.V.	
	A8	LE VAN KIM et al., "Molecular cloning and primary structure of the human blood group RhD polypeptide," <u>Proc. Natl. Acad. Sci. USA</u> , November 1992, pp. 10925-10929, Vol. 89	
	A9	MOURO et al., "Rearrangements of the Blood Group RhD Gene Associated with the D ^V Category Phenotype," <u>Blood</u> , February 15, 1994, pp. 1129-1135, Vol. 83, No. 4, The American Society of Hematology	
	A10	PARADIS et al., "Protective Effect of the Membrane Skeleton on the Immunologic Reactivity of the Human Red Cell Rh ₀ (D) Antigen," <u>The Journal of Immunology</u> , July 1, 1986, pp. 240-244, Vol. 137, No. 1, The American Association of Immunologies	
	A11	PERSSON et al., "Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning," <u>Proc. Natl. Acad. Sci. USA</u> , March 1991, pp. 2432-2436, Vol. 88	
	A12	RACE et al. (Eds.), <u>Blood Groups in Man</u> , 1975, TABLE OF CONTENTS ONLY, Blackwell Scientific Publications	

Examiner Signature		Date Considered	7/30/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

MAILED
MAY 06 2004
UNITED STATES PATENT AND TRADEMARK OFFICE

(use as many sheets as necessary)

2	of	2
---	----	---

Complete if Known	
Application Number	09/147,443
Filing Date	01/21/1999
First Named Inventor	Andreas Morell
Group Art Unit	1644
Examiner Name	Francois P. Vandervegt
Attorney Docket Number	029860-0114

[illegible]

Examiner Signature		Date Considered	7/30/04
-----------------------	---	--------------------	---------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.**